
Conference Coverage
36 minutes ago
AOA 2026: Helping patients brave the eye of the needleabout 8 hours ago
AOA 2026: Integrating a workhorse contact lens into your toolkitabout 24 hours ago
AOA 2026: Puzzling cases in myopia managementabout 1 month ago
ARVO 2026: Renaming artificial tearsLatest Content

AOA 2026: Helping patients brave the eye of the needle

Vision loss linked to higher cognitive impairment in nursing home residents

Novel multifocal toric daily disposable lens matches nontoric performance

AOA 2026: Integrating a workhorse contact lens into your toolkit

Systematic review links Demodex blepharitis to worse MGD severity
Shorts










Podcasts
Videos
Optometry Times Digital Edition





Continuing Medical Education
All News

For Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, myopia management is best started sooner rather than later.

A real-world pilot across 8 optometric sites found Qlosli (0.4% pilocarpine) implementation met or exceeded all corporate KPIs, with UWF imaging utilization rising 16.4 percentage points and 72.7% of patients achieving personal treatment goals.

GATHER2 OLE data through 3.5 years show avacincaptad pegol reduced GA lesion growth by 28.8% in continuously treated patients and 37% to 40% in those switched from sham, with no new safety signals.

Anna Tichenor, OD, PhD, FAAO, details her poster – one of AOA 2026's Top Five posters – that identified how quickly and how meaningfully patients experience symptom improvement, and which types of symptoms are affected.

A VA case report documents rapid PDR progression to intravitreal anti-VEGF treatment in a patient 6 months after semaglutide initiation, reinforcing AOA monitoring guidance for GLP-1 patients with preexisting DR.

Mohammad Rafieetary, OD, FAAO, FORS, DipABO, ABCMO, details his portion of the "Myopia Matters: Managing Risk, Vision Loss and Control" presentation.

Mark Wells, OD, weighs in on the new parameter range expected for the Acuvue Oasys 1-Day for Astigmatism lens.

Expanded astigmatism parameters are expected for PRECISION1, PRECISION7, and TOTAL30 contact lenses.

New preservative-free cyclosporine 0.05% single-use drops target dry eye inflammation, dosing, and safety.

Mile Brujic, OD, FAAO, details his presentation on how eye care providers can best equip themselves with identifying and mitigating toxicities caused by antibody drug conjugates.

New phase 3 trial tests rhNGF eye drops for persistent corneal epithelial defects, aiming for full healing and a first approved PCED therapy.

The company said the expanded portfolio will be available in the US and Canada this summer.

The investment will expand ACUVUE contact lens manufacturing and distribution in Jacksonville, improving supply chain stability for optometrists by 2028.

A newly developed diagnostic system, CaptureTumor (CaT), driven by AI and designed specifically for smartphone deployment, achieved diagnostic accuracy comparable to that of a specialist-graded slit-lamp evaluation for detecting rare ocular surface malignancies.

In this podcast, experts Francis Mah, MD; and Amy Nau, OD, FAAO, Dipl, CCLRT; discuss how to identify neurotrophic keratitis in practice, highlighting indications for corneal sensitivity testing based on patient history and examination findings. Faculty will also examine how to stage and treat neurotrophic keratitis once diagnosed.











































